secwatch.observer — SEC 8-K summary
======================================

Issuer:     DermTech, Inc. (—)
CIK:        0001651944
Form:       8-K
Filed at:   2023-06-28T23:59:59+00:00
Accession:  0001651944-23-000065
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DermTech: 15% workforce cut, pipeline suspended, cash runway to Q1 2025
-----------------------------------------------------------------------

- Reduction of ~40 employees (~15%), completion expected by end-of-July 2023.
- Annualized cost savings of $25M-$30M; one-time charge ~$2M in Q2 2023.
- All pipeline programs suspended; focus solely on DermTech Melanoma Test revenue.
- Cash runway extended into Q1 2025; $108.4M cash as of March 31, 2023.
- Chief Commercial Officer Todd Wood to depart July 3, 2023; separation terms pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651944/000165194423000065/0001651944-23-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651944/000165194423000065/dmtk-20230626.htm
  HTML page:      https://secwatch.observer/filing/0001651944-23-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer